This clinical guide provides an evidence-based roadmap for the non-operative management of osteoarthritis (OA), focusing on joint preservation, inflammation control, and neuromuscular capacity building for knee, hip, and hand joints.
While osteoarthritis (OA) is the most prevalent joint pathology, clinical evaluation must robustly distinguish it from alternative joint conditions and recognize key clinical "red flags" that require immediate emergency or specialist medical assessment.
Osteoarthritis must be clearly differentiated from the following clinical entities:
To safely distinguish routine OA from conditions requiring urgent or emergency intervention, clinicians monitor for the following clinical red flags:
Osteoarthritis is a chronic, progressive, whole-joint disease characterized by joint degradation, low-grade synovial inflammation (synovitis), osteophyte formation, and joint effusion [14]. Rather than a simple "wear-and-tear" phenomenon, OA represents a failure of joint homeostasis with active cartilage degradation, subchondral bone activity, and joint instability [5:5][14:1]. Certain anti-inflammatory agents, such as nimesulide, are utilized for acute flares due to their targeted pain management and protective properties against cartilage degradation [15].
The clinical diagnosis of osteoarthritis is established through a combination of history, physical examination, and radiographic verification. Under the American College of Rheumatology (ACR) criteria, a clinical diagnosis of knee OA can be made if chronic knee pain (lasting weeks) is accompanied by at least three of the following six findings: age over 50 years, morning joint stiffness lasting up to 30 minutes, crepitus on active motion, bony tenderness on palpation, bony enlargement (thickening), and no local heat on palpation [5:6].
Standard weight-bearing radiographs are the initial imaging modality of choice to confirm joint degeneration and rule out differential diagnoses [14:2][7:2]. Crucially, radiographic severity (such as Kellgren-Lawrence grading) does not correlate linearly with clinical symptoms; many patients with mild radiographic OA experience severe pain and functional limitations, whereas others with advanced radiographic joint space loss remain relatively asymptomatic [14:3].
Advanced imaging can be utilized selectively; for example, musculoskeletal ultrasound or Magnetic Resonance Imaging (MRI) may be indicated to evaluate suspected soft tissue, meniscus, ligament abnormalities, or subchondral insufficiency fractures [7:3][6:5].
Biomechanical functions, clinical presentations, and prognoses are joint-specific and cannot be generalized from one anatomical region to another:
| Intervention | Evidence | What to do | Notes |
|---|---|---|---|
| Land-Based Exercise | High | Supervised or self-directed progressive resistance training combined with low-impact aerobic conditioning (cycling, aquatic training). | Universal first-line baseline therapy. Rebuilds muscular capacity to support joint function [4:3][1:7]. |
| Weight Management | High | Implement structured weight reduction in individuals with knee and/or hip osteoarthritis who are overweight or obese [1:8]. | Strongly recommended for weight-bearing joints to alleviate mechanical joint stress, reduce pain, and improve overall physical function [1:9]. |
| Topical NSAIDs | High | Apply topical diclofenac gel or patch to the affected joint multiple times daily. | Strongly recommended for knee OA and conditionally recommended for hand OA under ACR/AF guidelines [1:10]. Provides effective localized pain relief with a lower risk of systemic cardiorenal and gastrointestinal adverse events compared to oral formulations [2:1]. |
| Oral NSAIDs & Coxibs | High | Utilize oral nonselective NSAIDs or selective COX-2 inhibitors (coxibs) for short-term management of moderate-to-severe pain. | Highly effective but carry serious cardiovascular and cardiorenal risks, serious gastrointestinal side effects, and serious cutaneous adverse reactions [16][1:11]. Use at the lowest effective dose for the shortest duration. |
| Intra-Articular Corticosteroids | Moderate | Administer intra-articular steroid injections for joint pain management. | Strongly recommended for knee OA and conditionally recommended for hand OA [1:12]. Corticosteroid injections are recommended for joint pain management under major guidelines [17][1:13]. |
| Tai Chi / Qigong | Moderate | Incorporate structured sessions of Tai Chi or Qigong. | Tai Chi is strongly recommended by ACR/AF [1:14]. Qigong is also studied with clinical benefits [17:1]. Both practices have been shown to reduce pain, improve physical function, and promote self-management [17:2][1:15]. |
| Assistive Devices & Splints | Moderate-to-High | Use hand orthoses for first CMC joint OA, tibiofemoral bracing for knee malalignment, or a cane in the contralateral hand. | Hand orthoses for first CMC joint OA, tibiofemoral bracing, and contralateral cane use are strongly recommended; other orthoses and braces are conditionally recommended [1:16]. These options support physical function, joint stability, and loading [3:4][1:17]. |
| Acupuncture | Moderate | Utilize as an adjunctive, non-pharmacological modality for chronic pain control. | Conditionally recommended as an evidence-based adjunctive/complementary treatment option for managing pain in hand, hip, and knee OA [17:3][1:18]. |
| Intra-Articular Hyaluronic Acid | Low-to-Moderate (Variable) | Consider viscosupplementation injections for localized knee pain in patients failing or intolerant to initial therapies. | Guidelines report variable clinical evidence. ACR 2012 guidelines conditionally recommended HA for patients with an inadequate response to initial therapies [4:4], with European consensus groups also outlining its clinical use [18]. |
| Chondroitin Sulfate | Low-to-Moderate | Consider oral chondroitin sulfate specifically for hand OA symptoms. | Conditionally recommended by ACR/AF for hand OA specifically, but not for knee and hip OA [1:19][19]. |
| Glucosamine & Chondroitin | Low / Insufficient Efficacy | Avoid prioritizing as a first-line clinical intervention. | Chondroitin sulfate is conditionally recommended specifically for hand OA under ACR/AF guidelines, but not listed for knee and hip OA [1:20]. Although these compounds demonstrate a favorable safety profile, clinical trials regarding their symptomatic and structure-modifying efficacy have yielded conflicting results [20]. Different clinical guidelines may show varying recommendations regarding these supplements due to differing evidence evaluation methodologies [21]. |
| Platelet-Rich Plasma (PRP) | Very Low / Investigational | Reserve for clinical trial settings or refractory cases under specialist guidance. | Positioned as investigational. A lack of standardized clinical evidence limits its endorsement in routine clinical practice guidelines. |
| Methylsulfonylmethane (MSM) | Very Low / Unsupported | Avoid prioritizing as a first-line clinical intervention. | Lacks robust, high-quality clinical trial data to support efficacy or warrant endorsement in professional guidelines. |
Multimodal exercise is the non-pharmacological cornerstone of osteoarthritis management [4:5][1:21]. For weight-bearing joints (knee, hip), low-impact cardiovascular conditioning and resistance exercises are strongly recommended [4:6][1:22]. These exercises help support joint stability and improve overall physical function.
For hand OA, structured therapy is broadly focused on joint protection techniques, assistive devices, and tailored hand exercises to manage pain, joint stiffness, and functional impairment [3:5][4:7][1:23]. Neuromuscular training, specifically Tai Chi, is strongly recommended by ACR/AF [1:24], while Qigong is also studied with clinical benefits [17:4]. These practices are noted for their clinical benefits in pain reduction, physical function, and promoting a sense of internal control and self-management [17:5][1:25].
For individuals with concomitant sarcopenia or physical frailty, maintaining and building skeletal muscle mass is vital for offloading arthritic joints; see the Sarcopenia & Frailty Prevention Guide or our dedicated clinical reference on Sarcopenia for targeted hypertrophy and strength protocols.
Structured weight reduction is strongly recommended in individuals with knee and/or hip osteoarthritis who are overweight or obese [1:26]. During normal ambulation, weight-bearing joints experience loads equivalent to several times total body weight, and structured weight loss contributes directly to reducing mechanical stress on weight-bearing joint structures [1:27].
Pharmacological interventions in osteoarthritis are targeted strictly at symptomatic pain control and joint inflammation, as there are currently no approved disease-modifying osteoarthritis drugs (DMOADs) capable of reversing cartilage degradation or restoring joint structure.
Joint injections serve as temporary, targeted bridge therapies to control severe localized symptoms and improve functional mobility, but they do not possess regenerative or disease-modifying potential.
Biomechanical unloading is a critical adjunctive strategy to protect degenerating joint structures and maintain functional independence.
Surgical treatment, specifically total or partial joint arthroplasty, is considered a last resort in the clinical algorithm for patients who have failed to respond to non-pharmacological and pharmacological treatment approaches and present with progressive limitations in their activities of daily living [22:1].
Implementing proactive wellness care and intentional preparation strategies prior to joint replacement surgery is a key clinical strategy to prevent postoperative complications and optimize patient outcomes [23]. Preparing patients for potential joint replacement when the diagnosis of osteoarthritis becomes evident provides them with the best opportunity for an optimal functional outcome following surgical intervention [23:1].
Systemic oral NSAIDs (both nonselective agents and selective COX-2 inhibitors) carry significant cardiorenal, cardiovascular, gastrointestinal, and cutaneous risks [16:3]. They must be used with extreme caution or avoided in patients with a history of congestive heart failure, hypertension, or other conditions conveying high cardiorenal or cardiovascular risks [16:4]. Patients at risk for upper gastrointestinal adverse events require careful selection, such as utilizing selective COX-2 inhibitors (coxibs) as an alternative to nonselective NSAIDs [22:2].
Intra-articular injections and topical therapies are utilized as adjunctive treatments to control pain [22:3]. However, systemic anti-inflammatory drugs and injections must be selected based on patient comorbidities, risk profiles, and clinical guidelines [16:5][22:4][1:40].
For acute diagnostic boundaries, including septic arthritis, acute crystal arthritis, traumatic joint injuries, and systemic inflammatory diseases, as well as critical red flags (systemic symptoms, inability to bear weight, hot swollen joints, and locking), refer to the Differential Diagnosis, Clinical Boundaries, and Red Flags section above.
For localized knee interventions and detailed progression models for lower-limb loading, refer to our Knee Pain Action Guide. To address systemic muscular capacity and build the skeletal muscle reserve necessary to offload degenerating joint structures, review our clinical guidelines on Sarcopenia or the Sarcopenia & Frailty Prevention Guide.
Longevipedia pages are AI-updated and human-reviewed. We prioritize human evidence from systematic reviews, registered clinical trials, and major clinical guidelines, updating our content dynamically as new clinical trial data and international rheumatological consensus updates emerge.
Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2020 Feb;72(2):149-162. https://pubmed.ncbi.nlm.nih.gov/31908149/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Current Medical Research and Opinion. 2011 Jul;27(7):1315-1327. https://pubmed.ncbi.nlm.nih.gov/21561395/ ↩︎ ↩︎ ↩︎
Fuggle N, Bere N, Bruyère O, et al. Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach. Aging Clinical and Experimental Research. 2022 Sep;34(9):1985-1995. https://pubmed.ncbi.nlm.nih.gov/35864304/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Sub-analysis of guidelines. Arthritis Care & Research. 2012 Apr;64(4):465-474. https://pubmed.ncbi.nlm.nih.gov/22563589/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Giwnewer U, Rubin G, Orbach H. Treatment for Osteoarthritis of the Knee. Harefuah. 2016 Jul;155(7):426-430. https://pubmed.ncbi.nlm.nih.gov/28514128/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Expert Panel on Musculoskeletal Imaging, Jacobson JA, Roberts CC, et al. ACR Appropriateness Criteria(®) Chronic Extremity Joint Pain-Suspected Inflammatory Arthritis. Journal of the American College of Radiology. 2017 May;14(5S):S81-S90. https://pubmed.ncbi.nlm.nih.gov/28473097/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Expert Panel on Musculoskeletal Imaging, Bateni CP, Ha AS, et al. ACR Appropriateness Criteria® Chronic Knee Pain: Update 2026. Journal of the American College of Radiology. 2026 Jun;23(6S):S1-S12. https://pubmed.ncbi.nlm.nih.gov/42340275/ ↩︎ ↩︎ ↩︎ ↩︎
Smolen JS, Collaud Basset S, Boers M, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases. 2016 Jul;75(7):1268-1271. https://pubmed.ncbi.nlm.nih.gov/27037326/ ↩︎
Antivalle M, Bertani L, Mutti A. [Clinical red flags vs laboratory red flags]. Reumatismo. 2006 Jan-Mar;58(1):54-61. https://pubmed.ncbi.nlm.nih.gov/23631061/ ↩︎ ↩︎
Eviltis E. [Differential diagnosis of acute arthritis]. Medicina (Kaunas). 2003;39(6):533-541. https://pubmed.ncbi.nlm.nih.gov/12794379/ ↩︎
Roll P, Kleinert S, Tony HP. [Acute monarthritis]. MMW Fortschritte der Medizin. 2007 Nov 1;149(44):29-31. https://pubmed.ncbi.nlm.nih.gov/18078170/ ↩︎ ↩︎
Sack K. Monarthritis: differential diagnosis. The American Journal of Medicine. 1997 Jan 27;102(1A):30S-34S. https://pubmed.ncbi.nlm.nih.gov/9217557/ ↩︎ ↩︎
Migliore A, Scirè CA, Carmona L, et al. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. Rheumatology International. 2017 Aug;37(8):1227-1236. https://pubmed.ncbi.nlm.nih.gov/28451793/ ↩︎ ↩︎
Zacher J, Carl HD, Swoboda B. Imaging of osteoarthritis of the peripheral joints. Zeitschrift für Rheumatologie. 2007 May;66(3):215-224. https://pubmed.ncbi.nlm.nih.gov/17051361/ ↩︎ ↩︎ ↩︎ ↩︎
Applying the evidence in osteoarthritis: strategies for pain management. Clinical Drug Investigation. 2007 Dec;27(12):801-815. https://pubmed.ncbi.nlm.nih.gov/23392787/ ↩︎ ↩︎ ↩︎
Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clinical Rheumatology. 2006;25 Supp 1:S6-10. https://pubmed.ncbi.nlm.nih.gov/16741783/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Irnich D, Bäumler P. Concept for integrative pain treatment of osteoarthritis of the knee based on the evidence for conservative and complementary therapies. Schmerz. 2023 Dec;37(6):423-433. https://pubmed.ncbi.nlm.nih.gov/37505229/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Jerosch J. Injection treatment with hyaluronic acid. Zeitschrift für Rheumatologie. 2015 Nov;74(9):794-802. https://pubmed.ncbi.nlm.nih.gov/26431953/ ↩︎ ↩︎
Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology. 2020 Feb;72(2):220-233. https://pubmed.ncbi.nlm.nih.gov/31908163/ ↩︎
Henrotin Y, Lambert C. Chondroitin and glucosamine in the management of osteoarthritis: an update. Current Rheumatology Reports. 2013 Oct;15(10):361. https://pubmed.ncbi.nlm.nih.gov/23955063/ ↩︎
Roddy E, Doherty M. Guidelines for management of osteoarthritis published by the American College of Rheumatology and the European League Against Rheumatism: why are they so different? Rheumatic Diseases Clinics of North America. 2003 Nov;29(4):747-763. https://pubmed.ncbi.nlm.nih.gov/14603579/ ↩︎
Schnitzer TJ, American College of Rheumatology. Update of ACR guidelines for osteoarthritis: role of the coxibs. Journal of Pain and Symptom Management. 2002 Apr;23(4 Suppl):S24-30. https://pubmed.ncbi.nlm.nih.gov/11992747/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Pearson SH. Proactive Wellness Care for Patients with Osteoarthritis. The Nursing Clinics of North America. 2020 Jun;55(2):193-201. https://pubmed.ncbi.nlm.nih.gov/32389249/ ↩︎ ↩︎
Peter WF, Jansen MJ, Hurkmans EJ, et al. Physiotherapy in hip and knee osteoarthritis: development of a practice guideline concerning initial assessment, treatment and evaluation. Acta Reumatologica Portuguesa. 2011 Jul-Sep;36(3):269-281. https://pubmed.ncbi.nlm.nih.gov/22113602/ ↩︎
van Doormaal MCM, Meerhoff GA, Vliet Vlieland TPM, et al. A clinical practice guideline for physical therapy in patients with hip or knee osteoarthritis. Musculoskeletal Care. 2020 Dec;18(4):575-589. https://pubmed.ncbi.nlm.nih.gov/32643252/ ↩︎